Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 4642

Drug Profile

HRS 4642

Alternative Names: HRS-4642

Latest Information Update: 03 Nov 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class 2 ring heterocyclic compounds; Antineoplastics; Azabicyclo compounds; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Naphthols; Oxazepines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Adenocarcinoma
  • Phase I/II Solid tumours

Most Recent Events

  • 30 Oct 2026 Shanghai Hengrui Pharmaceutical plans a phase I pharmacokinetics trial for Pancreatic cancer (In volunteers) in China (IV) (NCT07906691)
  • 28 Oct 2026 Shanghai Hengrui Pharmaceutical plans a phase III trial for Pancreatic cancer (First line therapy, Combination therapy) in China (Injection) (NCT07900789)
  • 26 Oct 2026 The Third Xiangya Hospital of Central South University plans a phase I pharmacokinetic trial in Healthy adult volunteer in October 2026 (IV, Infusion) (NCT07894679)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top